REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Companyâs NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Companyâs mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Companyâs NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Companyâs third-party licensees. Source
No articles found.
SaRA helps improve care for employees and reduce costs for employers, especially f...
SaRA helps improve care for employees and reduc...
Zoi, on a basic level, is an app that integrates with an Apple Watch and other wea...
Zoi, on a basic level, is an app that integrate...
Gali Health, Inc. is a San Francisco-based consumer-focused health technology comp...
Gali Health, Inc. is a San Francisco-based cons...
Founded in 1999, Dexcom, Inc. is the leader in transforming diabetes care and mana...
Founded in 1999, Dexcom, Inc. is the leader in ...
CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues ...
CollPlant is a regenerative medicine company fo...
LogicBio is a Cambridge, MA-based genome editing company focused on delivering the...
LogicBio is a Cambridge, MA-based genome editin...
Voyager Therapeutics is developing life-changing gene therapies for fatal and debi...
Voyager Therapeutics is developing life-changin...
Join the National Investor Network and get the latest information with your interests in mind.